(Reuters) -The U.S. Food and Drug Administration has approved Regeneron's cancer therapy, the company said on Wednesday, ...

Regeneron will not acquire 23andMe’s telehealth subsidiary, Lemonaid Health, which the company purchased for approximately $400 million in 2021.

Regeneron's co-founder, Dr. George D. Yancopoulos, who is also the company's president and chief scientific officer, described the 23andMe acquisition as part of Regeneron's strategy to use DNA ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Genetic testing firm 23andMe is set to be acquired by drug company Regeneron Pharmaceuticals following its bankruptcy in March, the companies announced on Monday, May 19.

Regeneron Pharmaceuticals said it will acquire "substantially all" of 23andMe's assets. The genetic testing company filed for Chapter 11 bankruptcy protection in March.